JM

Jessica Moon

VP @ The Implementation Group (TIG) | Included VC - Cohort Member (Class โ€˜24) | GoingVC Partner, Health Tech | Gies MBA '27

Washington DC-Baltimore Area

Work Experience

  • Vice President

    2025

    ๐—” ๐˜€๐˜๐—ฟ๐—ฎ๐˜๐—ฒ๐—ด๐—ถ๐—ฐ ๐—ฐ๐—ผ๐—ป๐˜€๐˜‚๐—น๐˜๐—ถ๐—ป๐—ด ๐—ณ๐—ถ๐—ฟ๐—บ ๐˜๐—ต๐—ฎ๐˜ ๐—ต๐—ฒ๐—น๐—ฝ๐˜€ ๐—ผ๐—ฟ๐—ด๐—ฎ๐—ป๐—ถ๐˜‡๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€ ๐˜€๐—ฒ๐—ฐ๐˜‚๐—ฟ๐—ฒ ๐—ณ๐˜‚๐—ป๐—ฑ๐—ถ๐—ป๐—ด. Advise research-driven for-profit and nonprofit clientsโ€”including healthtech startups and research institutionsโ€”on securing competitive federal and private funding. Focus on funding strategy, positioning, proposal development, and evaluation to help teams compete and scale. Draw on a background in biomedical research and venture capital to support clients in healthtech and adjacent sectors. www.tigdc.com

  • Venture Capital Cohort Member (Class '24)

    2024

    ๐—” โ€˜๐˜‚๐—ป๐—ถ๐—พ๐˜‚๐—ฒ ๐—ณ๐—ฎ๐˜€๐˜-๐˜๐—ฟ๐—ฎ๐—ฐ๐—ธ ๐— ๐—•๐—” ๐—ณ๐—ผ๐—ฟ ๐˜ƒ๐—ฒ๐—ป๐˜๐˜‚๐—ฟ๐—ฒ ๐—ฐ๐—ฎ๐—ฝ๐—ถ๐˜๐—ฎ๐—นโ€™ ๐—ณ๐—ผ๐—ฟ ๐—ฒ๐˜…๐˜๐—ฟ๐—ฎ๐—ผ๐—ฟ๐—ฑ๐—ถ๐—ป๐—ฎ๐—ฟ๐˜† ๐—น๐—ฒ๐—ฎ๐—ฑ๐—ฒ๐—ฟ๐˜€. ๐—œ๐—ป๐—ฐ๐—น๐˜‚๐—ฑ๐—ฒ๐—ฑ ๐—ฉ๐—– ๐—ถ๐˜€ ๐˜๐—ต๐—ฒ ๐—ณ๐—ถ๐—ฟ๐˜€๐˜ & ๐—ผ๐—ป๐—น๐˜† ๐—ผ๐—ณ ๐—ถ๐˜๐˜€ ๐—ธ๐—ถ๐—ป๐—ฑ ๐—ด๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—ณ๐˜‚๐—น๐—น๐˜† ๐—ณ๐˜‚๐—ป๐—ฑ๐—ฒ๐—ฑ ๐—™๐—ฒ๐—น๐—น๐—ผ๐˜„๐˜€๐—ต๐—ถ๐—ฝ ๐—ณ๐—ผ๐—ฟ ๐—ถ๐—ป๐—ฑ๐—ถ๐˜ƒ๐—ถ๐—ฑ๐˜‚๐—ฎ๐—น๐˜€ ๐—ณ๐—ฟ๐—ผ๐—บ ๐—ผ๐˜ƒ๐—ฒ๐—ฟ๐—น๐—ผ๐—ผ๐—ธ๐—ฒ๐—ฑ & ๐—ฑ๐—ถ๐˜ƒ๐—ฒ๐—ฟ๐˜€๐—ฒ ๐—ฐ๐—ผ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐˜๐—ถ๐—ฒ๐˜€. Over 75% of those Fellows that were actively looking for a role have broken into the venture capital ecosystem globally โ€“ from Asia to Europe to Africa to the Americas. Included VC is supported by an international consortium of venture capital partners and sponsors including: BITKRAFT, Creandum, Daphni, European Investment Fund, Esprit Foundation, HSBC Ventures, HV Capital, Mouro Capital, Mangrove Capital, Notion Capital, Seedcamp and Wilson Sonsini. Included VC has been featured by the likes of Forbes, Sky News, CNBC & Business Insider.

  • Venture Partner, Health Tech

    2024

    ๐—”๐—ป ๐—ฎ๐—ป๐—ด๐—ฒ๐—น ๐˜€๐˜†๐—ป๐—ฑ๐—ถ๐—ฐ๐—ฎ๐˜๐—ฒ ๐—ฎ๐—ป๐—ฑ ๐˜ƒ๐—ฒ๐—ป๐˜๐˜‚๐—ฟ๐—ฒ ๐—ฐ๐—ฎ๐—ฝ๐—ถ๐˜๐—ฎ๐—น ๐˜๐—ฟ๐—ฎ๐—ถ๐—ป๐—ถ๐—ป๐—ด ๐—ฝ๐—ฟ๐—ผ๐—ด๐—ฟ๐—ฎ๐—บ ๐˜„๐—ต๐—ฒ๐—ฟ๐—ฒ ๐—œ ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ๐—ฑ ๐—ฎ๐—ป๐—ฑ ๐—ฒ๐˜ƒ๐—ฎ๐—น๐˜‚๐—ฎ๐˜๐—ฒ๐—ฑ ๐—ต๐—ฒ๐—ฎ๐—น๐˜๐—ต ๐˜๐—ฒ๐—ฐ๐—ต ๐˜€๐˜๐—ฎ๐—ฟ๐˜๐˜‚๐—ฝ๐˜€, ๐˜€๐˜‚๐—ฝ๐—ฝ๐—ผ๐—ฟ๐˜๐—ฒ๐—ฑ ๐—ณ๐—ผ๐˜‚๐—ป๐—ฑ๐—ฒ๐—ฟ๐˜€ ๐˜„๐—ถ๐˜๐—ต ๐—ณ๐˜‚๐—ป๐—ฑ๐—ฟ๐—ฎ๐—ถ๐˜€๐—ถ๐—ป๐—ด ๐˜€๐˜๐—ฟ๐—ฎ๐˜๐—ฒ๐—ด๐—ถ๐—ฒ๐˜€ Source, diligence, and pitch investment opportunities in health tech. Advise founders on growth strategies and connect them with resources.

2024 - 2025

  • Founder

    2024 - 2025

    BioMed VC Insights (BVCI) was born out of a simple observation: founders building breakthrough biomedical solutions often struggle with one of the most critical partsโ€”funding. BVCI helps founders bridge the gap between non-dilutive and venture capital financing. Through Funding for Founders (https://www.bvci.io/), I provide plainspoken strategies, resources, and tools to demystify grant fundingโ€”especially NIH and SBIR/STTR. My work combines deep grant expertise with a venture-informed perspective, helping founders make smarter decisions across their entire funding journey.

  • Executive Director, Longevity, Equity, and Aging Research Consortium (formerly SAGE)

    2020 - 2025

    ๐—”๐—ป ๐—ฎ๐—ฐ๐—ฎ๐—ฑ๐—ฒ๐—บ๐—ถ๐—ฐ ๐—ฐ๐—ผ๐—ป๐˜€๐—ผ๐—ฟ๐˜๐—ถ๐˜‚๐—บ ๐—ณ๐—ผ๐—ฐ๐˜‚๐˜€๐—ฒ๐—ฑ ๐—ผ๐—ป ๐—ฎ๐—ฑ๐˜ƒ๐—ฎ๐—ป๐—ฐ๐—ถ๐—ป๐—ด ๐—ฎ๐—ด๐—ถ๐—ป๐—ด ๐—ฎ๐—ป๐—ฑ ๐—น๐—ผ๐—ป๐—ด๐—ฒ๐˜ƒ๐—ถ๐˜๐˜† ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐˜๐—ผ ๐—ถ๐—บ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฒ ๐˜๐—ต๐—ฒ ๐—พ๐˜‚๐—ฎ๐—น๐—ถ๐˜๐˜† ๐—ผ๐—ณ ๐—น๐—ถ๐—ณ๐—ฒ ๐—ผ๐—ณ ๐—ผ๐—น๐—ฑ๐—ฒ๐—ฟ ๐—ฎ๐—ฑ๐˜‚๐—น๐˜๐˜€, ๐˜„๐—ต๐—ฒ๐—ฟ๐—ฒ ๐—œ ๐—น๐—ฒ๐—ฑ ๐—ถ๐—ป๐—ถ๐˜๐—ถ๐—ฎ๐˜๐—ถ๐˜ƒ๐—ฒ๐˜€ ๐˜๐—ผ ๐—ถ๐—ป๐—ฐ๐—ฟ๐—ฒ๐—ฎ๐˜€๐—ฒ ๐—ฑ๐—ถ๐˜ƒ๐—ฒ๐—ฟ๐˜€๐—ถ๐˜๐˜† ๐—ถ๐—ป ๐—ฏ๐—ถ๐—ผ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฐ๐—ฎ๐—น ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ฎ๐—ป๐—ฑ ๐—ฏ๐˜‚๐—ถ๐—น๐˜ ๐˜€๐—ฐ๐—ฎ๐—น๐—ฎ๐—ฏ๐—น๐—ฒ ๐—ฝ๐—ฟ๐—ผ๐—ด๐—ฟ๐—ฎ๐—บ ๐—ถ๐—ป๐—ณ๐—ฟ๐—ฎ๐˜€๐˜๐—ฟ๐˜‚๐—ฐ๐˜๐˜‚๐—ฟ๐—ฒ. Manage the seed grant program with 22 projects on developing patient-centric solutions in digital health technologies, disease diagnostics, and tools for drug development. Acquired $4M in grant funding for biomedical and clinical research projects. Transformed the SAGE Research Center into the Longevity, Equity, and Aging Research Consortium by building key partnerships with 3 academic institutions, 2 healthcare networks in California, and various community organizations. Manage compliance for 25 biomedical and clinical trials, ensuring adherence to institutional and federal regulations.

2018 - 2020

  • Research Development Associate, Biomedical Sciences, Research Development Services

    2018 - 2020

    ๐—”๐—ป ๐—ฅ๐Ÿญ ๐—ฎ๐—ฐ๐—ฎ๐—ฑ๐—ฒ๐—บ๐—ถ๐—ฐ ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ถ๐—ป๐˜€๐˜๐—ถ๐˜๐˜‚๐˜๐—ถ๐—ผ๐—ป ๐˜„๐—ต๐—ฒ๐—ฟ๐—ฒ ๐—œ ๐˜€๐—ฒ๐—ฐ๐˜‚๐—ฟ๐—ฒ๐—ฑ $๐Ÿฏ๐Ÿญ๐—  ๐—ถ๐—ป ๐—ฏ๐—ถ๐—ผ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฐ๐—ฎ๐—น ๐—ณ๐˜‚๐—ป๐—ฑ๐—ถ๐—ป๐—ด ๐—ฎ๐—ป๐—ฑ ๐—ฑ๐—ฒ๐˜€๐—ถ๐—ด๐—ป๐—ฒ๐—ฑ ๐—ด๐—ฟ๐—ฎ๐—ป๐˜ ๐—ฝ๐—ฟ๐—ผ๐—ด๐—ฟ๐—ฎ๐—บ๐˜€ ๐˜๐—ผ ๐˜€๐˜‚๐—ฝ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—ฒ๐—ฑ๐˜‚๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—ฎ๐—ฐ๐—ฐ๐—ฒ๐˜€๐˜€ ๐—ณ๐—ผ๐—ฟ ๐˜‚๐—ป๐—ฑ๐—ฒ๐—ฟ๐˜€๐—ฒ๐—ฟ๐˜ƒ๐—ฒ๐—ฑ ๐—ฐ๐—ผ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐˜๐—ถ๐—ฒ๐˜€. Consulted with biomedical researchers in the 5 health science colleges on project design, resulting in acquisition of $31M in research grant funding in 2 years. Presented 41 seminars and workshops on biomedical project design, human subjects research compliance, identifying funding opportunities, effective pitching/communication, and building partnerships.

2017 - 2019

  • Specialist Editor, Biochemistry, Genetics, and Molecular Biology

    2017 - 2019

    ๐—” ๐—ด๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐˜€๐—ฐ๐—ถ๐—ฒ๐—ป๐˜๐—ถ๐—ณ๐—ถ๐—ฐ ๐—ฐ๐—ผ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€ ๐—ฐ๐—ผ๐—บ๐—ฝ๐—ฎ๐—ป๐˜† ๐˜„๐—ต๐—ฒ๐—ฟ๐—ฒ ๐—œ ๐—ฒ๐—ฑ๐—ถ๐˜๐—ฒ๐—ฑ ๐—ฎ๐—ป๐—ฑ ๐—ฐ๐—ผ๐—ป๐˜€๐˜‚๐—น๐˜๐—ฒ๐—ฑ ๐—ผ๐—ป ๐—ฏ๐—ถ๐—ผ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฐ๐—ฎ๐—น ๐˜„๐—ฟ๐—ถ๐˜๐—ถ๐—ป๐—ด ๐—ฝ๐—ฟ๐—ผ๐—ท๐—ฒ๐—ฐ๐˜๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—ฝ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ฒ๐˜‚๐˜๐—ถ๐—ฐ๐—ฎ๐—น ๐—ฎ๐—ป๐—ฑ ๐—ฎ๐—ฐ๐—ฎ๐—ฑ๐—ฒ๐—บ๐—ถ๐—ฐ ๐—ฐ๐—น๐—ถ๐—ฒ๐—ป๐˜๐˜€. Consulted on and edited 140 biomedical writing projects across therapeutic areas for drug companies and academic investigators, including primary research articles, review articles, and an Investigational New Drug (IND) application.

2017 - 2017

  • Biomedical Research and Funding Consultant

    2017 - 2017

    Consulted on research portfolio development, biomedical project design, and funding acquisition, resulting in acquisition of a prestigious grant and publication of 5 peer-reviewed manuscripts.